In a research report released Sunday, Oppenheimer analyst Christopher Marai maintained an Outperform rating on Uniqure NV (NASDAQ:QURE) with a price target of $47, which implies an upside of 48% from current levels.
Marai noted, “2H15 readout for AMT-060 represents significant catalyst for QURE, supporting that AAV5-FIX gene therapy results in appropriate gene-expression and is well tolerated for long-term prophylactic Hemophilia B treatment. AAV8-to-AAV5 switch is a focus of P2 results; further described pp. 4-5.” Furthermore, “AMT-110 for Sanfilippo-B in our view remains an attractive, underappreciated ultra-rare disease asset, data 3Q15.”
Bottom line: “We recommend owning QURE into two 2H15 readouts: Phase I/II data for AMT-060 (FIX gene) in Hemophilia B and Phase I/II data for AMT-110 (NaGLU) in Sanfilippo B/MPSIII.”
According to TipRanks.com, which measures analysts’ and bloggers’ success rate based on how their calls perform, analyst Christopher Marai has a total average return of 46.5% and a 77.8% success rate. Marai has a 18.8% average return when recommending QURE, and is ranked #6 out of 3638 analysts.
All the 6 analysts polled by TipRanks rate Uniqure NV stock a Buy. With a return potential of 34.5%, the stock’s consensus target price stands at $42.60.